Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 8 per cent on Friday after the pharmaceutical group announced positive results from the latest trial of weight-loss treatments.

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

There’s a little problem, though: most of the decline in the seven comes down to one company. Apple is down 14 per cent since ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...